{"id":"lubiprostone-amitiza","safety":{"commonSideEffects":[{"rate":"29","effect":"Nausea"},{"rate":"12","effect":"Diarrhea"},{"rate":"13","effect":"Abdominal pain"},{"rate":"11","effect":"Headache"},{"rate":"7","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lubiprostone is a prostaglandin F analog that selectively activates ClC-2 chloride channels on the apical membrane of gastrointestinal epithelial cells. This activation increases chloride and fluid secretion into the intestinal lumen, which increases stool frequency and softens stool consistency. The mechanism does not depend on neural or hormonal pathways, making it effective across various types of constipation.","oneSentence":"Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel movements.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:39.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic idiopathic constipation"},{"name":"Irritable bowel syndrome with constipation (IBS-C)"},{"name":"Opioid-induced constipation"}]},"trialDetails":[{"nctId":"NCT07405736","phase":"PHASE2","title":"Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis","enrollment":124},{"nctId":"NCT07277907","phase":"PHASE3","title":"Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2025-11-13","conditions":"Slow Transit Constipation, Pharmacotherapy","enrollment":346},{"nctId":"NCT04361656","phase":"","title":"The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2020-05-01","conditions":"Colonoscopy Preparation","enrollment":""},{"nctId":"NCT03720613","phase":"","title":"Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation","status":"RECRUITING","sponsor":"BioDelivery Sciences International","startDate":"2019-01-04","conditions":"Opioid-induced Constipation","enrollment":34532},{"nctId":"NCT06543979","phase":"PHASE1, PHASE2","title":"Anorectal Manometery in Pediatric Chronic Refractory Constipation","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-09-07","conditions":"Chronic Constipation","enrollment":60},{"nctId":"NCT05768334","phase":"PHASE3","title":"Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-01","conditions":"NAFLD","enrollment":116},{"nctId":"NCT01839734","phase":"PHASE2","title":"Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy","status":"COMPLETED","sponsor":"Ruth M. Rothstein CORE Center","startDate":"2013-06","conditions":"HIV","enrollment":20},{"nctId":"NCT00645801","phase":"PHASE4","title":"Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2008-03","conditions":"Colonoscopy","enrollment":158},{"nctId":"NCT00908076","phase":"PHASE4","title":"Amitiza in Constipation Associated With PD (Parkinson's Disease)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-02","conditions":"Parkinson's Disease","enrollment":78},{"nctId":"NCT04861233","phase":"","title":"A Study of Lubiprostone to Treat Constipation","status":"UNKNOWN","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2021-09-01","conditions":"Constipation","enrollment":3000},{"nctId":"NCT05144295","phase":"PHASE3","title":"Lubiprostone for Functional Constipation in the Under 18 Years Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-01-01","conditions":"Clinical Efficacy, Treatment Efficacy, Drug Side Effect","enrollment":274},{"nctId":"NCT04985669","phase":"PHASE4","title":"Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-08-15","conditions":"Patient Satisfaction","enrollment":140},{"nctId":"NCT04138004","phase":"PHASE4","title":"Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2019-12-01","conditions":"Indication for Modification of Patient Status (Diagnosis)","enrollment":140},{"nctId":"NCT01096290","phase":"PHASE4","title":"Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications","status":"TERMINATED","sponsor":"University of South Alabama","startDate":"2010-04","conditions":"Constipation","enrollment":23},{"nctId":"NCT00746395","phase":"PHASE4","title":"Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy","status":"COMPLETED","sponsor":"University of South Alabama","startDate":"2008-04","conditions":"Inflammatory Bowel Disease","enrollment":45},{"nctId":"NCT02481947","phase":"PHASE3","title":"A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults","status":"COMPLETED","sponsor":"Braintree Laboratories","startDate":"2015-05","conditions":"Chronic Idiopathic Constipation","enrollment":459},{"nctId":"NCT02042183","phase":"PHASE3","title":"Lubiprostone in Children With Functional Constipation","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2013-12-13","conditions":"Constipation - Functional","enrollment":606},{"nctId":"NCT02766777","phase":"PHASE3","title":"Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2016-04-12","conditions":"Constipation - Functional","enrollment":87},{"nctId":"NCT03010631","phase":"PHASE3","title":"Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2016-11-16","conditions":"Healthy Volunteers","enrollment":49},{"nctId":"NCT01298219","phase":"PHASE3","title":"Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2010-12","conditions":"Opioid-induced Bowel Dysfunction","enrollment":439},{"nctId":"NCT00620061","phase":"PHASE3","title":"Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2007-12","conditions":"Opioid-Induced Bowel Dysfunction","enrollment":439},{"nctId":"NCT02138136","phase":"PHASE3","title":"Lubiprostone for Children With Constipation","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2014-02-26","conditions":"Constipation - Functional","enrollment":419},{"nctId":"NCT03097861","phase":"PHASE3","title":"Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2017-03-13","conditions":"Chronic Idiopathic Constipation","enrollment":552},{"nctId":"NCT02544152","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome","status":"TERMINATED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2015-02","conditions":"Irritable Bowel Syndrome","enrollment":71},{"nctId":"NCT00399542","phase":"PHASE3","title":"Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2005-05","conditions":"Irritable Bowel Syndrome, Constipation","enrollment":581},{"nctId":"NCT00452335","phase":"PHASE4","title":"Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2007-01","conditions":"Constipation","enrollment":127},{"nctId":"NCT00595946","phase":"PHASE3","title":"Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2007-08","conditions":"Opioid-Induced Bowel Dysfunction","enrollment":439},{"nctId":"NCT01993875","phase":"PHASE3","title":"Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2013-10","conditions":"Chronic Idiopathic Constipation","enrollment":164},{"nctId":"NCT00597428","phase":"PHASE3","title":"Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2007-08","conditions":"Opioid-Induced Bowel Dysfunction","enrollment":437},{"nctId":"NCT00380250","phase":"PHASE3","title":"Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2005-05","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":590},{"nctId":"NCT02729909","phase":"PHASE3","title":"Lubiprostone for Chronic Idiopathic Constipation Treatment","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-05-11","conditions":"Constipation","enrollment":211},{"nctId":"NCT01190020","phase":"PHASE1","title":"Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.","status":"COMPLETED","sponsor":"Augusta University","startDate":"2009-02","conditions":"Chronic Constipation, Methanogenesis","enrollment":41},{"nctId":"NCT02695719","phase":"PHASE3","title":"Lubiprostone for Treatment of Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04-14","conditions":"Chronic Idiopathic Constipation","enrollment":156},{"nctId":"NCT02651155","phase":"PHASE3","title":"Lubiprostone for the Treatment of Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-02","conditions":"Constipation","enrollment":204},{"nctId":"NCT01460225","phase":"PHASE4","title":"Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2007-09","conditions":"Chronic Idiopathic Constipation","enrollment":19},{"nctId":"NCT00844831","phase":"PHASE4","title":"Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2009-05","conditions":"Constipation","enrollment":25},{"nctId":"NCT01469819","phase":"PHASE2, PHASE3","title":"Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2012-06","conditions":"Chronic Idiopathic Constipation","enrollment":37},{"nctId":"NCT01447849","phase":"PHASE2, PHASE3","title":"Lubiprostone and Mucus Secretion in Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2011-08","conditions":"Constipation","enrollment":40},{"nctId":"NCT01162863","phase":"NA","title":"Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2010-11","conditions":"Irritable Bowel Syndrome, Constipation","enrollment":60},{"nctId":"NCT00669461","phase":"NA","title":"Lubiprostone as a Treatment for Constipation in Parkinson's Disease","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2009-06","conditions":"Constipation, Parkinson's Disease","enrollment":1},{"nctId":"NCT01170039","phase":"PHASE4","title":"The Effectiveness of Lubiprostone in Constipated Diabetics","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-09","conditions":"Constipation, Diabetes","enrollment":121},{"nctId":"NCT01236534","phase":"PHASE4","title":"Lubiprostone in Patients With Multiple Sclerosis Associated Constipation","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-11","conditions":"Multiple Sclerosis, Constipation","enrollment":21},{"nctId":"NCT00577499","phase":"","title":"Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2007-10","conditions":"Cystic Fibrosis, Constipation, Nutrition","enrollment":7},{"nctId":"NCT00689026","phase":"NA","title":"Efficacy of Lubiprostone in Combination With Standard PEG Preparation","status":"TERMINATED","sponsor":"Augusta University","startDate":"2008-05","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT01674530","phase":"PHASE3","title":"Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2012-10","conditions":"Chronic Idiopathic Constipation","enrollment":909},{"nctId":"NCT00934479","phase":"PHASE1","title":"Intestinal Microecology in Chronic Constipation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-04","conditions":"Other Constipation, Irritable Bowel Syndrome","enrollment":21},{"nctId":"NCT01324284","phase":"PHASE3","title":"Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy","status":"COMPLETED","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2011-03","conditions":"Colorectal Carcinoma","enrollment":442},{"nctId":"NCT00662363","phase":"NA","title":"Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation","status":"COMPLETED","sponsor":"Shirley Ryan AbilityLab","startDate":"2008-04","conditions":"Constipation","enrollment":64},{"nctId":"NCT00953017","phase":"PHASE4","title":"A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2009-07","conditions":"Colonoscopy","enrollment":425},{"nctId":"NCT00611442","phase":"NA","title":"Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2007-10","conditions":"Bowel Preparation for Colonoscopy","enrollment":191},{"nctId":"NCT01372423","phase":"PHASE3","title":"Evaluation of Clinical Equivalence Between Two Lubiprostone Products","status":"COMPLETED","sponsor":"Anchen Pharmaceuticals, Inc","startDate":"2011-05","conditions":"Chronic Idiopathic Constipation","enrollment":808},{"nctId":"NCT00953043","phase":"PHASE4","title":"Lubiprostone, Colonic Motility and Sensation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-09","conditions":"Healthy","enrollment":60},{"nctId":"NCT01085643","phase":"NA","title":"Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2010-03","conditions":"Constipation-predominant Irritable Bowel Syndrome","enrollment":4},{"nctId":"NCT01166789","phase":"PHASE1","title":"Lubiprostone Effects on Visceral Pain Sensitivity","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-02","conditions":"Irritable Bowel Syndrome","enrollment":62},{"nctId":"NCT00706004","phase":"NA","title":"Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Constipation, Cystic Fibrosis","enrollment":9},{"nctId":"NCT00985569","phase":"","title":"Surveying The Outcomes Of Lubiprostone (The STOOL Study) in Nursing Home Residents","status":"WITHDRAWN","sponsor":"Synergy Health Solutions","startDate":"2009-11","conditions":"Constipation","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amitiza"],"phase":"marketed","status":"active","brandName":"lubiprostone (Amitiza)","genericName":"lubiprostone (Amitiza)","companyName":"Henry Ford Health System","companyId":"henry-ford-health-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel movements. Used for Chronic idiopathic constipation, Irritable bowel syndrome with constipation (IBS-C), Opioid-induced constipation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}